Fibrocell Science Inc (FCSC) : Context Capital Management reduced its stake in Fibrocell Science Inc by 42.72% during the most recent quarter end. The investment management company now holds a total of 15,300 shares of Fibrocell Science Inc which is valued at $16,524 after selling 11,410 shares in Fibrocell Science Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Fibrocell Science Inc makes up approximately 0.14% of Context Capital Management’s portfolio.
Other Hedge Funds, Including , Walleye Trading reduced its stake in FCSC by selling 1,300 shares or 96.87% in the most recent quarter. The Hedge Fund company now holds 42 shares of FCSC which is valued at $45. Alpine Partners Vi added FCSC to its portfolio by purchasing 32,057 company shares during the most recent quarter which is valued at $34,622. Fibrocell Science Inc makes up approx 0.02% of Alpine Partners Vi’s portfolio. Tiaa Cref Investment Management sold out all of its stake in FCSC during the most recent quarter. The investment firm sold 82,089 shares of FCSC which is valued $88,656.Vanguard Group Inc reduced its stake in FCSC by selling 63,655 shares or 4.68% in the most recent quarter. The Hedge Fund company now holds 1,296,907 shares of FCSC which is valued at $1,400,660. Geduld E E sold out all of its stake in FCSC during the most recent quarter. The investment firm sold 20,000 shares of FCSC which is valued $22,200.
Fibrocell Science Inc closed down -0.0601 points or -6.26% at $0.8999 with 1,34,994 shares getting traded on Thursday. Post opening the session at $0.95, the shares hit an intraday low of $0.88 and an intraday high of $0.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Fibrocell Science Inc. (Fibrocell) is an autologous cell therapy company focused on developing treatments for rare and serious skin and connective tissue diseases. The Company’s lead orphan gene therapy program is in late-stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In addition to its gene therapy program the Company is pursuing the medical application of azficel-T for vocal cord scarring using its autologous fibroblast technology. The Company is also in pre-clinical development for its second gene therapy program for linear scleroderma. The Company’s collaboration with Intrexon Corporation a synthetic biology company includes using genetically modifying autologous fibroblast cells to express collagen VII that is missing or inactive from patients with RDEB.